Investment
Features
FeesSafety
Academy
More
Pluang+
|
Home/News Feed/Regeneron agrees with US government to cut drug prices and offer free gene therapy for rare hearing loss
REGN
$650.20
-$14.25 -2.14%

Regeneron agrees with US government to cut drug prices and offer free gene therapy for rare hearing loss

Market News
24 Apr 2026
Vandana Singh
View Source
Bullish
pluang ai news

Regeneron Pharmaceuticals has reached a deal with the US government to lower drug prices by aligning Medicaid pricing with other developed countries and offering direct purchase options for its cholesterol drug Praluent. The company will provide its newly FDA-approved gene therapy Otarmeni for rare genetic hearing loss free of charge in the US. This agreement includes Regeneron's commitment to invest over $9 billion in US research and manufacturing, while avoiding future pricing mandates and gaining tariff relief. The deal aims to improve drug accessibility and support domestic innovation.

More News (REGN)

Baird's international and global growth funds underperform MSCI benchmarks in Q2 2026.

Baird's international and global growth funds underperform MSCI benchmarks in Q2 2026.

In Q2 2026, Baird's Chautauqua International Growth Fund returned +10.39%, trailing the MSCI ACWI ex-U.S. Index's +14.49%. Key detractors included Alibaba and Lululemon, while Recruit and ASML contributed positively. The Global Growth Fund also lagge...

Market News
Neutral
2 days ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App